Source: Clinical Nuclear Medicine. Unidade: FM
Subjects: DOENÇA DE GRAVES (CINTILOGRAFIA;DIAGNÓSTICO), SEGUIMENTOS, RADIOMETRIA, RADIOIMUNOENSAIO (USO TERAPÊUTICO), DOSIMETRIA, HIPERTIREOIDISMO (USO TERAPÊUTICO)
ABNT
WILLEGAIGNON, José S e SAPIENZA, Marcelo e BUCHPIGUEL, Carlos. Radioiodine Therapy for Graves Disease: Thyroid Absorbed Dose of 300 Gy—Tuning the Target for Therapy Planning. Clinical Nuclear Medicine, v. 38, n. 4, p. 231-236, 2013Tradução . . Disponível em: https://doi.org/10.1097/RLU.0b013e3182816717. Acesso em: 09 out. 2024.APA
Willegaignon, J. S., Sapienza, M., & Buchpiguel, C. (2013). Radioiodine Therapy for Graves Disease: Thyroid Absorbed Dose of 300 Gy—Tuning the Target for Therapy Planning. Clinical Nuclear Medicine, 38( 4), 231-236. doi:10.1097/RLU.0b013e3182816717NLM
Willegaignon JS, Sapienza M, Buchpiguel C. Radioiodine Therapy for Graves Disease: Thyroid Absorbed Dose of 300 Gy—Tuning the Target for Therapy Planning [Internet]. Clinical Nuclear Medicine. 2013 ; 38( 4): 231-236.[citado 2024 out. 09 ] Available from: https://doi.org/10.1097/RLU.0b013e3182816717Vancouver
Willegaignon JS, Sapienza M, Buchpiguel C. Radioiodine Therapy for Graves Disease: Thyroid Absorbed Dose of 300 Gy—Tuning the Target for Therapy Planning [Internet]. Clinical Nuclear Medicine. 2013 ; 38( 4): 231-236.[citado 2024 out. 09 ] Available from: https://doi.org/10.1097/RLU.0b013e3182816717